Compare Global X Defense Tech ETF (SHLD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Zimmer Biomet Holdings Inc — how do they compare? Global X Defense Tech ETF trades at $69.69, while Zimmer Biomet Holdings Inc trades at $95.96 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals.
| SHLD | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $107.71 |
52-Week Low | $58.20 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD, the Global X Defense Tech ETF, trades at $69.74, down slightly by 0.16% today. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights increased institutional investment, with firms like Focus Financial Network raising stakes by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF benefits from global defense spending trends, including a $20 billion UK military overhaul (Zacks Investment Research, 2026-07-02).
The outlook for SHLD is positive, driven by rising global defense budgets and technological advancements in defense sectors. Investment opportunities include diversified exposure to defense innovation, supported by institutional accumulation. Risks involve geopolitical shifts, potential tariff impacts from policies like Trump's new tariffs (Fool - Investing News, 2026-08-04), and valuation pressures if growth slows. The ETF's performance hinges on sustained military expenditure increases and contract awards.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
